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The main objective of this project was to evaluate pretargeting systems that use a bispecific 
antibody (bsMAb) to improve the detection and treatment of cancer. A bsMAb has specificity to 
a tumor antigen, which is used to bind the tumor, while the other specificity is to a peptide that 
can be radiolabeled. Pretargeting is the process by which the unlabeled bsMAb is given first, and 
after a sufficient time (1-2 days) is given for it to localize in the tumor and clear from the blood, 
a small molecular weight radiolabeled peptide is given. According to a dynamic imaging study 
using a 99mTc-labeled peptide, the radiolabeled peptide localizes in the tumor in less than 1 
hour, with > 80% of it clearing from the blood and body within this same time. Tumodnontumor 
targeting ratios that are nearly 50 times better than that with a directly radiolabeled Fab’ 
fragment have been observed (Sharkey et al., “Signal amplification in molecular imaging by a 
multivalent bispecific nanobody” submitted). The bsMAbs used in this project have been 
composed of 3 antibodies that will target antigens found in colorectal and pancreatic cancers 
(CEA, CSAp, and MUC1). For the “peptide binding moiety” of the bsMAb, we initially 
examined an antibody directed to DOTA, but subsequently focused on another antibody directed 
against a novel compound, HSG (histamine-succinyl-glycine). 
Maior Accomplishments: 
The initial goal of this project was the development of a pretargeting system based on the LG-1 
anti-DOTA antibody. A chemically conjugated Fab’ x Fab’ bispecific antibody (bsMAb) was 
prepared with an anti-CEA (carcinoembryonic antigen) antibody and targeting examined in nude 
mice bearing colorectal cancer xenografts (Losman et al., Proc. Am. Assoc. for Cancer Res., 
44:1290,2003). Although reasonable targeting of an 11 1In-labeled peptide was achieved within 
3 hours, over time the radioactivity washed out of the tumor more quickly than other pretargeting 
systems using the same anti-CEA antibody, but different anti-hapten antibodies. Ultimately, 
BIAcore analysis showed that the affinity of LG1 Fab’ was significantly reduced compared to 
the IgG. Further analysis showed LG- 1 was binding specifically to the DOTA, but it also 
required a lysine linkage. This suggested that LG-1 not only recognized the DOTA, but that its 
specificity likely required some portion of the carrier that was used as the immunogen. An 
attempt was made to develop a new anti-DOTA antibody. For thls purpose, two groups of mice 
were immunized, one with KLH (keyhole limpet hemocyanin) conjugated to peptide IMP 258 
(Ac-Lys(D0TA)-Cys-NHz) through a thioether linkage, and the other with an IgG-DOTA 
conjugate that was used to prepare the LG-1 anti-DOTA antibody. The former represented an 
attempt to develop an antibody response more specific for a DOTA-peptide that could be used in 
pretargeting, whereas the former simply looked to reproduce our previous attempt. Following 
fusion, cloning and recloning, at least 10 possible candidate clones were identified from the 
DOTA-peptide immunogen, but after recloning, either the clones were not stable or the antibody 
binding properties were not sufficient to warrant further development. Thus, we formally closed 
this line of investigation and more aggressively pursued another pretargeting systems using the 
anti-HSG (histamine-succinyl-glycine) hapten bindi t b t W  eat 
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success (Sharkey et al., Cancer Res., 63:354-63,2003). Using this system in conjunction with an 
anti-CEA antibody for tumor targeting, extended biodistribution studies have shown pretargeting 
is able to deliver about 1.5 - to 2.0- times the radiation dose to a tumor as a directly radiolabeled 
anti-CEA antibody at equitoxic doses, with a dose rate that is 3 times that of a 90Y-labeled IgG 
(Sharkey et al., Clin. Cancer Res., 9:3897s-3913sY 2003). In addition, the dose rate to the tumor 
is nearly tripled. This pretargeting system, now using a novel recombinant trivalent bsMAb 
(Rossi et al., “Pretargeting of CEA-expressing cancers with a trivalent bispecific fusion protein 
produced in myeloma cells.” Clin Cancer Res., in press). Over the last year, a number of therapy 
studies have been performed in the GW-39 colorectal cancer model that examined whether 
pretargeting using the anti-CEA bsMAb and a 90Y-labeled peptide was superior to a 9OY- 
labeled anti-CEA IgG. These studies have included determinations of maximally tolerated doses 
in the nude mice for both the 90Y-IgG and the 90Y-peptide under optimal pretargeting 
conditions. Therapy studies were then set up to examine a range of 90Y-radioactivity doses 
proportional to the maximum tolerated dose in animals bearing subcutaneous tumors of varying 
size. Both of these treatments are fairly effective in nude mouse models, and therefore 
observations are continuing because an extended period of time is required to observe potential 
differences. One study was terminated after 14 weeks, because the 90Y-IgG dose given in this 
study was beyond the MTD (i.e., lead to several treatment-related deaths), whereas the dose of 
90Y-labeled peptide was well tolerated. Thus, continued comparison of efficacy in this study 
would not have fairly compared each treatment at equitoxic doses of radioactivity &e., the 90Y- 
IgG group was overdosed). Nevertheless, in examining survival as defined by the time it took for 
tumors to reach 2.5 cm3 (starting tumor size was 0.5 cm3), at 14 weeks, 7/10 animals in the 
pretargeting group had tumors < 2.5 cm3, whereas the median “survival” for the ”Y-IgG group 
was reached. Histological examination of the 7 tumor masses taken from the pretargeting group 
revealed 3 were completed devoid of viable tissue. Thus, this pretargeting treatment, which 
was safely tolerated in all animals, resulted in a 30% cure rate of substantially sized (0.7 
grams) tumors. Two of the other 4 tumors had only a single microscopic focus of viable tumor, 
which would have taken many more weeks to progress to 2.5 cm3. The other 2 tumors were 
composed of approximately 30 to 70% viable tumor cells, but they were -1 .O cm3 (they had 
reached this size just 2-weeks after treatment when all growth was arrested), and therefore would 
have required several more weeks before reaching 2.5 cm3. Thus, although 50% of the surviving 
animals in the 90Y-IgG group had reached a tumor size of 2.5 cm3 at the termination of the study 
(median survival 14 weeks), the median survival for the ”Y-peptide pretargeting group had not 
been reached at this time, and would have likely extended considerably longer had the study not 
been terminated. 
Several other studies have now been completed with monitoring periods as long a 36-weeks. As 
in these earlier studies, the data continue to support the improved therapeutic outcome with the 
pretargeting approach compared to the direct targeting. 
Pretargeting Colorectal Cancer using Mu-9 anti-CSAp bsMAb 
Mu-9 is a MAb directed against an antigen found primarily in colorectal cancers. Preclinical 
studies showed improved targeting and retention of radiolabeled Mu-9 compared to our anti- 
CEA antibodies, suggesting that Mu-9 might have an advantage in the therapy of colorectal 
cancer. Thus, our objective was to determine whether a bsMAb composed of Mu9 would have 
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an advantage over bsMAb directed to CEA for pretargeting. A humanized version of Mu-9 has 
been prepared and this was used to make M u 9  x m679 Fab' x Fab' bsMAb. Biodistribution 
studies in nude mice bearing colorectal cancer xenografts have been performed with the directly 
radioiodinated IgG, F(ab')2, Fab' of Mu-9 and the bsMAb. The F(ab')2 and the Fab' fragments 
cleared rapidly from blood, and there was evidence that the F(ab')z was not stable in the blood. 
However, studies with the chemically stabilized Mu-9 Fab' x Fab' bsMAb showed the expected 
stability that has been observed with other bsMAb prepared using this method. When used in 
pretargeting, tumor uptake an '"In-labeled peptide was 23.5 k 4.4 % injected dose (ID)/g within 
3 h and was maintained at this level for 2 days, and even 5 days later, 13.6 k 3.6 % ID/g 
remained in the tumor. Tumorhontumor ratios at 3 h were 9: 1 , 5:  1, and > 25: 1 for the blood, 
kidney, and other major organs. Analysis of area under the curve (AUC) over 5 days showed 
pretargeting with the Mu-9 bsMAb was nearly 2-fold higher than that seen with pretargeting 
using the directly radiolabeled Mu-9 IgG over a similar period, and with a 3-fold higher radiation 
dose rate. Tumorhontumor ratios based on the AUC were 45 : 1 , 8: 1 , and 32: 1 for the blood, 
kidney, and liver, respectively However, it is equally important to note that this represents a 
significant improved compared to the excellent pretargeting results achieved with the anti-CEA 
bsMAb pretargeting system. 
Pretargeting Pancreatic Cancer cPAM4 anti-MUC-1 x m734 anti-(1n)DTPA 
The primary rationale for exploring pretargeting in pancreatic cancer is the recent work by 
investigators at our institution with a 90Y-labeled anti-MUC- 1 antibody, PAM4. In preclinical 
studies, treatment of CAPANl human pancreatic cancer xenografts in nude mice with 260 uCi of 
"Y-labeled cPAM4 IgG showed effective anti-tumor effects. However, more importantly, when 
only 25 uCi of 90Y-cPAh44 IgG (that delivered a dose of only 800 cGy to the tumor) was 
combined with a full course of gemcitabine, the only approved treatment for pancreatic cancer 
that also serves as a radiosensitizer, significantly improved anti-tumor effects were achieved 
(Gold et al., Clin. Cancer Res., 3929~-3937s, 2003). 90Y-hpAh44 IgG is now being studied 
clinically, but we already are anticipating that a pretargeting approach with PAM4 will have the 
added advantage of reducing hematologic toxicity, but with the ability to deliver the same or 
more radiation dose to the tumor as the radiolabeled IgG. This is important since gemcitabine is 
myelosuppressive. 
A bsMAb using cPAM4 Fab' and the anti-hapten antibody m734, an anti-indium-loaded DTPA 
antibody, was prepared and pretargeting tested in nude mice bearing human CaPanl pancreatic 
cancer xenografts (Cardillo et al., Clin Cancer Res., 10:3552-3461 , 2004). Biodistribution studies 
of the bsMAb alone and pretargeting studies using a 99mTc- and an "'In-labeled peptide were 
performed. High tumor uptake (-20 % lD/g at 3 h post peptide injection) and retention was 
observed with both of these peptides. Peptide tumor uptake was negligible with the control group 
pretargeted with the non-specific bsMAb and also in a group that received the peptide alone. 
Peptide tumorhon-tumor ratios were high as early as 3 h post peptide injection. These studies 
show promise for imaging and therapy of pancreatic cancer with pretargeting. We are in the 
process of preparing bsMAb with the PAM4 and anti-HSG antibody to evaluate therapeutic 
issues for pancreatic cancer. 
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Importantly, each of the targeting systems listed above, CEA, CSAp and MUC1 can be used in 
pancreatic cancer. Thus, we are also planning to pursue an evaluation of using this trio of bsMAb 
for targeting pancreatic cancer in animal models. However, while we have shown each of these 
antigens to be present in fresh human pancreatic cancer tissue, we will first need to select 
appropriate cell lines that express all 3 antigens to pursue t b s  line of investigation. 
Treatment of Non-Hodgkin’s Lymphoma using hA20 anti-CD20 x m679 anti-HSG bsMAb 
Based on the encouraging therapeutic advantage reported by investigators at the University of 
Washington with a streptavidin-anti-CD20 pretargeting system in NHL, we decided to explore 
the potential of the bsMAb pretargeting approach for NHL. Our rationale for pursuing this 
approach is that streptavidin is immunogenic, even in NHL patients, and thus, by using a bsMAb 
that is humanized, we would avoid, or at least significantly reduce this problem. In addition, 
although 2 FDA-approved anti-CD20 antibody therapeutics are already available for NHL, the 
data from the University of Washington suggest that pretargeting should have a therapeutic 
advantage with less toxicity. Our goal is to assess whether a bsMAb pretargeting approach could 
achieve similar success. 
A bsMAb using hA20, a humanized antibody to CD20 was prepared with the anti-HSG antibody. 
The biodistribution of the bsMAb alone and in a pretargeting system with an 1 1 1 In-labeled 
peptide have been examined in SCID mice bearing Raji human Burkett’s lymphoma cell line. In 
pretargeting, peptide uptake was similar to values reported by the University of Washington 
investigators with the Ramos xenografts bearing mice, but with even better tumorhlood ratios. 
Three pilot therapy studies in nude mice bearing 2 1 .O cm diameter Ramos human B-cell 
lymphoma xenografts have shown the pretargeting approach using 90Y-labeled peptide is 
superior to the directly 90Y-labeled anti-CD20 IgG in the Ramos B-cell lymphoma cell line. 
[Sharkey et al., “Improving the treatment of non-Hodgkin’s lymphoma using radionuclides 
pretargeted with a new anti-CD20 bispecific antibody.” (submitted).] Thus, these preliminary 
studies confirm the superiority of pretargeting in B-cell lymphoma using the anti-CD20 x anti- 
HSG pretargeting system. 
Publications: Over the course of this project, a number of abstracts were submitted for 
presentation to national meetings (SNM, AACR, etc.). The listing below shows several articles 
have been published or recently submitted. We are in the process of preparing 2 additional 
manuscripts that will describe (a) a comparison of the targeting with various forms of 
molecularly engineered, recombinant bsMAb, and (b) summary of the therapy studies in the 
human colorectal cancer model comparing pretargeting and directly targeted antibodies. 
Articles: 
Cardillo TM, Karacay H, Goldenberg DM, Yeldell D, Chang CH, Modrak DE, Sharkey 
RM, Gold DV. Improved targeting of pancreatic cancer: experimental studies of a new 
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Cancer Res. 2004 May 15;10(10):3552-61. 
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